Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Comparing peer multi-asset models
Neil compares BridgeBio to models like Roivant and Nimbus and why BridgeBio chose a different public approach.
Play episode from 31:50
Transcript
